Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) SEC filings page on Stock Titan brings together the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents provide structured insight into KalVista’s financial condition, governance, capital structure and key events related to its development and commercialization of EKTERLY (sebetralstat), an oral plasma kallikrein inhibitor for hereditary angioedema (HAE).
Investors can review Form 8‑K current reports in which KalVista announces material events, such as FDA approval of EKTERLY, preliminary and quarterly financial results, appointments of new executives and directors, and the issuance of 3.250% Convertible Senior Notes due 2031. These filings describe terms of financing arrangements, board and committee changes, executive employment agreements and stock‑based inducement awards.
Proxy materials such as the DEF 14A definitive proxy statement detail corporate governance matters, including annual meeting agendas, director elections, advisory votes on executive compensation and auditor ratification. They also outline board structure, committee responsibilities and stockholder voting procedures. Periodic reports referenced in the proxy statement, such as the company’s Annual Report on Form 10‑K, provide audited financial statements and broader business discussion.
Through Stock Titan, users can access these filings as they are made available on EDGAR and use AI‑powered summaries to interpret complex sections, including descriptions of convertible note covenants, events of default, change‑in‑control provisions and compensation arrangements. The filings page is also a key source for tracking any future Forms 3, 4 and 5 that would report insider transactions in KalVista common stock, as well as 10‑Q and 10‑K reports that update on revenue from EKTERLY, research and development spending and liquidity.
By reviewing KalVista’s SEC filings with the help of AI explanations, investors can better understand how the company finances its operations, governs its business and discloses risks and opportunities associated with its rare‑disease portfolio.
KalVista Pharmaceuticals (KALV) disclosed an employment agreement for a newly named executive, Mr. Arif, detailing compensation and termination protections. The agreement sets a $520,000 base salary and an annual bonus target equal to 40% of base salary. Mr. Arif will receive stock options to purchase 100,000 shares that vest over four years with 1/4 vesting after one year and thereafter 1/48th monthly vesting, subject to continued service.
If terminated by the company without cause or by Mr. Arif for good reason, he is entitled to a lump-sum payment equal to 12 months of base salary and 12 months of COBRA reimbursement. Within two years after a defined change in control, similar termination triggers (company without cause or employee for good reason) add a lump-sum payment equal to 12 months of base salary, a lump-sum equal to his full target bonus for the fiscal year, 12 months of COBRA reimbursement, and full vesting of outstanding unvested equity awards (with performance awards deemed at target or actual if determinable).
The filing includes a Form of Indemnification Agreement reference and notes a press release dated October 6, 2025, signed by CFO Brian Piekos.
KalVista Pharmaceuticals, Inc. director Brian JG Pereira was granted a stock option on 10/01/2025 to buy 30,000 shares of common stock at a conversion price of $12.05. The option was reported on Form 4 filed on 10/02/2025 and is exercisable in installments over a 12-month vesting schedule beginning 11/01/2025, with 1/12th of the total shares vesting initially and then monthly thereafter, subject to continued service. The option expires on 09/30/2035. Following the grant, Mr. Pereira directly beneficially owns 30,000 option shares.
Stuart Nancy, a director of KalVista Pharmaceuticals, Inc. (KALV), was granted a stock option on 10/01/2025 to buy 30,000 shares of common stock at an exercise price of $12.05 per share. The option vests over a 12‑month period, with the first 1/12th vesting on November 1, 2025 and then monthly thereafter, subject to continued service. The option expires on 09/30/2035. After the reported transaction, the filing shows 30,000 shares beneficially owned following the grant, held directly. The Form 4 was signed by an attorney‑in‑fact, Benjamin L. Palleiko, on 10/02/2025.
KalVista Pharmaceuticals, Inc. (KALV) director William Fairey reported the vesting of a stock option award. On 10/01/2025 a grant coded as a vesting event (Code V) covered 30,000 stock options with an exercise price of $12.05. Following the reported transaction, the filing shows 30,000 shares beneficially owned directly. The option vests over a 12‑month period, beginning with 1/12th vesting on November 1, 2025 and then monthly thereafter, subject to continued service. The filing is signed by attorney‑in‑fact Benjamin L. Palleiko on 10/02/2025.
Edward W. Unkart, a director of KalVista Pharmaceuticals, Inc. (KALV), reported an acquisition of a stock option on 10/01/2025. The option grants the right to buy 30,000 shares of common stock at an exercise price of $12.05. The option vests over a 12‑month period beginning with a first vesting of 1/12th on November 1, 2025, then monthly thereafter, subject to continued service. The option becomes exercisable and expires on 09/30/2035, and the reporting person is shown as holding 30,000 shares beneficially following the transaction. The Form 4 was signed on behalf of the reporting person on 10/02/2025.
KalVista Pharmaceuticals, Inc. disclosed the appointment of Ms. Sensenig as a non-employee director and the associated compensation arrangements. Her initial board award consists of options to purchase 45,000 shares of the company's common stock. She will receive an annual cash retainer of $42,500 plus an additional $10,000 per year for service on the Audit Committee. The disclosure is a routine corporate governance item describing director pay terms.
KalVista Pharmaceuticals, Inc. filed an 8-K reporting the execution of an indenture for a new convertible debt instrument and related press releases. The filing references an indenture dated September 29, 2025 between the company and U.S. Bank Trust Company, N.A., which includes the form of 3.250% Convertible Senior Notes due 2031. The company also filed two press releases dated September 24, 2025 announcing the proposed offering and the pricing of the Notes, and submitted the Cover Page Interactive Data File. The filing is signed by Brian Piekos, Chief Financial Officer.
KalVista Pharmaceuticals, Inc. (KALV) reported mixed operational and clinical disclosures in this 10-Q excerpt. The company had a 100.0 million share registration ("ATM Shares") available under an S-3 prospectus supplement but did not offer or sell any ATM Shares during the three months ended July 31, 2025. Trade accounts receivable arise from product sales to specialty distributors and pharmacies; as of April 30, 2025 the company reported $0 of accounts receivable, net related to product sales and no reserve for credit losses. The filing describes fair value sensitivity for a derivative liability and discloses a $132.3 million royalty obligation as of July 31, 2025, with an embedded derivative carrying a fair value of $9.4 million. A licensing arrangement (Kaken Agreement) included an $11.0 million non-refundable upfront payment, potential regulatory and sales milestones of approximately $13.0 million, and effective royalties in the mid-twenties percent on Japanese pricing, for a 10-year initial term. The company also details commercial terms tied to annual net sales thresholds and a $50.0 million sales-based milestone if sebetralstat achieves at least $550.0 million in annual net sales before 2031. Clinically, EKTERLY (sebetralstat) is described as an oral, on-demand HAE therapy; 600 mg dosing showed statistically significant faster reduction in attack severity (p=0.0032) and faster complete attack resolution (p<0.0001) versus placebo.
KalVista Pharmaceuticals, Inc. filed a current report to share its financial results for the fiscal quarter ended July 31, 2025. The results are contained in a press release furnished as Exhibit 99.1.
The company specifies that this earnings information is furnished under Item 2.02 of the Exchange Act, not deemed filed, and it is signed on behalf of the company by Chief Executive Officer Benjamin L. Palleiko.
Insider transactions by KalVista Pharmaceuticals (KALV): Benjamin L. Palleiko, the company's Chief Executive Officer and a director, received 15,625 restricted stock units (RSUs) on 09/06/2025 that vest in equal quarterly installments (1/16th each) beginning June 6, 2024, and represent one share each on settlement. Upon vesting, 7,294 shares were sold on 09/08/2025 at an average price of $15.84 to satisfy tax-withholding obligations (a "sell to cover"). Following these events he beneficially owns 395,189 shares.